Cargando…

TrkB-Target Galectin-1 Impairs Immune Activation and Radiation Responses in Neuroblastoma: Implications for Tumour Therapy

Galectin-1 (Gal-1) has been described to promote tumour growth by inducing angiogenesis and to contribute to the tumour immune escape. We had previously identified up-regulation of Gal-1 in preclinical models of aggressive neuroblastoma (NB), the most common extracranial tumour of childhood. While G...

Descripción completa

Detalles Bibliográficos
Autores principales: Batzke, Katharina, Büchel, Gabriele, Hansen, Wiebke, Schramm, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877579/
https://www.ncbi.nlm.nih.gov/pubmed/29498681
http://dx.doi.org/10.3390/ijms19030718
_version_ 1783310723925934080
author Batzke, Katharina
Büchel, Gabriele
Hansen, Wiebke
Schramm, Alexander
author_facet Batzke, Katharina
Büchel, Gabriele
Hansen, Wiebke
Schramm, Alexander
author_sort Batzke, Katharina
collection PubMed
description Galectin-1 (Gal-1) has been described to promote tumour growth by inducing angiogenesis and to contribute to the tumour immune escape. We had previously identified up-regulation of Gal-1 in preclinical models of aggressive neuroblastoma (NB), the most common extracranial tumour of childhood. While Gal-1 did not confer a survival advantage in the absence of exogenous stressors, Gal-1 contributed to enhanced cell migratory and invasive properties. Here, we review these findings and extend them by analyzing Gal-1 mediated effects on immune cell regulation and radiation resistance. In line with previous results, cell autonomous effects as well as paracrine functions contribute to Gal-1 mediated pro-tumourigenic functions. Interfering with Gal-1 functions in vivo will add to a better understanding of the role of the Gal-1 axis in the complex tumour-host interaction during immune-, chemo- and radiotherapy of neuroblastoma.
format Online
Article
Text
id pubmed-5877579
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-58775792018-04-09 TrkB-Target Galectin-1 Impairs Immune Activation and Radiation Responses in Neuroblastoma: Implications for Tumour Therapy Batzke, Katharina Büchel, Gabriele Hansen, Wiebke Schramm, Alexander Int J Mol Sci Review Galectin-1 (Gal-1) has been described to promote tumour growth by inducing angiogenesis and to contribute to the tumour immune escape. We had previously identified up-regulation of Gal-1 in preclinical models of aggressive neuroblastoma (NB), the most common extracranial tumour of childhood. While Gal-1 did not confer a survival advantage in the absence of exogenous stressors, Gal-1 contributed to enhanced cell migratory and invasive properties. Here, we review these findings and extend them by analyzing Gal-1 mediated effects on immune cell regulation and radiation resistance. In line with previous results, cell autonomous effects as well as paracrine functions contribute to Gal-1 mediated pro-tumourigenic functions. Interfering with Gal-1 functions in vivo will add to a better understanding of the role of the Gal-1 axis in the complex tumour-host interaction during immune-, chemo- and radiotherapy of neuroblastoma. MDPI 2018-03-02 /pmc/articles/PMC5877579/ /pubmed/29498681 http://dx.doi.org/10.3390/ijms19030718 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Batzke, Katharina
Büchel, Gabriele
Hansen, Wiebke
Schramm, Alexander
TrkB-Target Galectin-1 Impairs Immune Activation and Radiation Responses in Neuroblastoma: Implications for Tumour Therapy
title TrkB-Target Galectin-1 Impairs Immune Activation and Radiation Responses in Neuroblastoma: Implications for Tumour Therapy
title_full TrkB-Target Galectin-1 Impairs Immune Activation and Radiation Responses in Neuroblastoma: Implications for Tumour Therapy
title_fullStr TrkB-Target Galectin-1 Impairs Immune Activation and Radiation Responses in Neuroblastoma: Implications for Tumour Therapy
title_full_unstemmed TrkB-Target Galectin-1 Impairs Immune Activation and Radiation Responses in Neuroblastoma: Implications for Tumour Therapy
title_short TrkB-Target Galectin-1 Impairs Immune Activation and Radiation Responses in Neuroblastoma: Implications for Tumour Therapy
title_sort trkb-target galectin-1 impairs immune activation and radiation responses in neuroblastoma: implications for tumour therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877579/
https://www.ncbi.nlm.nih.gov/pubmed/29498681
http://dx.doi.org/10.3390/ijms19030718
work_keys_str_mv AT batzkekatharina trkbtargetgalectin1impairsimmuneactivationandradiationresponsesinneuroblastomaimplicationsfortumourtherapy
AT buchelgabriele trkbtargetgalectin1impairsimmuneactivationandradiationresponsesinneuroblastomaimplicationsfortumourtherapy
AT hansenwiebke trkbtargetgalectin1impairsimmuneactivationandradiationresponsesinneuroblastomaimplicationsfortumourtherapy
AT schrammalexander trkbtargetgalectin1impairsimmuneactivationandradiationresponsesinneuroblastomaimplicationsfortumourtherapy